Merck’s $2.75bn acquisition of VelosBio: Strengthening its oncology pipeline
In a strategic move to bolster its oncology portfolio, U.S. pharmaceutical giant Merck & Co. has announced the acquisition of VelosBio, a clinical-stage biopharmaceutical company ... Read More
Seattle Genetics signs $4.4bn worth oncology deals with Merck
US biotech company Seattle Genetics has secured deals worth up to $4.4 billion with Merck, that include two new strategic oncology collaborations. The two major ... Read More
AstraZeneca strikes $6bn worth deal for Daiichi Sankyo’s DS-1062
AstraZeneca has signed a deal potentially worth up to $6 billion with Daiichi Sankyo for the global development and commercialization for the latter's DS-1062, a ... Read More
Olema Oncology raises $54m for breast cancer drug candidate OP-1250
Olema Oncology, a California-based biopharma company focused on developing targeted therapies for women's cancers, has raised $54 million in a Series B financing round, which ... Read More
Genetron Health’s semiconductor-based NGS system gets Chinese approval
Genetron Health has been granted approval by China’s National Medical Products Administration (NMPA) for GENETRON S5, its semiconductor-based next-generation sequencing system (NGS system). With the ... Read More
GE Healthcare unveils Serena Bright mammography solution for biopsy
GE Healthcare has unveiled new Serena Bright, a contrast-enhanced mammography solution for biopsy, which is claimed to help clinicians to detect breast cancer patients in ... Read More
Pharma giants bag Lynparza EMA approval for metastatic breast cancer
Lynparza EMA approval : Pharma giants AstraZeneca and MSD have secured an expansion of the European Medical Agency's (EMA) approval for their poly ADP-ribose polymerase ... Read More
Genentech gets Kadcyla FDA approval for post-surgery treatment of HER2+ EBC
Kadcyla FDA approval : Roche subsidiary Genentech has secured approval from the US Food and Drug Administration (FDA) for its breast cancer drug Kadcyla (ado-trastuzumab ... Read More
Ibrance FDA approval : Pfizer breast cancer drug approved for metastatic breast cancer in men
New Ibrance FDA approval : The US Food and Drug Administration (FDA) has extended the approval of Pfizer breast cancer drug Ibrance (palbociclib) to cover ... Read More
GSK completes $5.1bn acquisition of Tesaro to boost oncology pipeline
GlaxoSmithKline (GSK), the British pharmaceutical powerhouse, has successfully concluded its $5.1 billion acquisition of Tesaro, a leading oncology-focused biopharmaceutical company based in Waltham, Massachusetts. This ... Read More